RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Recordati Industria Chimica e Farmaceutica SpA Stock

Recordati Industria Chimica e Farmaceutica SpA P/E 2025

Recordati Industria Chimica e Farmaceutica SpA P/E

19.34

Ticker

REC.MI

ISIN

IT0003828271

WKN

A0EABR

As of Jan 30, 2025, Recordati Industria Chimica e Farmaceutica SpA's P/E ratio was 19.34, a 2.98% change from the 18.78 P/E ratio recorded in the previous year.

The Recordati Industria Chimica e Farmaceutica SpA P/E history

Recordati Industria Chimica e Farmaceutica SpA Aktienanalyse

What does Recordati Industria Chimica e Farmaceutica SpA do?

Recordati Industria Chimica e Farmaceutica SpA is an Italian pharmaceutical company based in Milan. The company was founded in 1926 by Giovanni Recordati and now has branches in many countries worldwide. Recordati's business model is based on the development, production, and marketing of drugs for various therapeutic areas. The company focuses particularly on therapy areas such as cardiology, urology, gastroenterology, pneumology, and hematology. Recordati operates in four business areas: Innovative Medicines, OTC Medicines, Generics, and Licensed Products. In the area of innovative medicines, the company specializes in the development of new active substances for the treatment of rare diseases. In the OTC Medicines area, Recordati specializes in the manufacture and marketing of over-the-counter drugs used to treat mild to moderate complaints. The generics area includes the production and marketing of generic products with the aim of influencing price development in the market. In the Licensed Products area, Recordati collaborates with other companies and takes over the marketing of their products in certain regions. Some of Recordati's best-known products include Cariprazine (an antipsychotic), Urolith (a preventive treatment for kidney stones), Zanipress (a treatment for hypertension), and Fokusin (a treatment for benign prostatic hyperplasia). Recordati is also committed to improving access to life-saving medications worldwide. The company engages in collaborations with international organizations such as the Global Alliance for TB Drug Development and supports the WHO's "Target Product Profiles" initiative. In 2019, Recordati Industria Chimica e Farmaceutica SpA achieved sales of around 1.4 billion euros in over 90 countries. The company employs about 4,200 people worldwide, including approximately 500 researchers and developers. In terms of future direction, Recordati sees continued high potential for growth and expansion, particularly through targeted investments in research and development. The company relies on close cooperation with other partners within the industry and the exploration of new markets and therapeutic areas. Recordati Industria Chimica e Farmaceutica SpA ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Recordati Industria Chimica e Farmaceutica SpA's P/E Ratio

The Price to Earnings (P/E) Ratio of Recordati Industria Chimica e Farmaceutica SpA is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Recordati Industria Chimica e Farmaceutica SpA's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Recordati Industria Chimica e Farmaceutica SpA is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Recordati Industria Chimica e Farmaceutica SpA’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Recordati Industria Chimica e Farmaceutica SpA stock

What is the price-to-earnings ratio of Recordati Industria Chimica e Farmaceutica SpA?

The price-earnings ratio of Recordati Industria Chimica e Farmaceutica SpA is currently 19.34.

How has the price-earnings ratio of Recordati Industria Chimica e Farmaceutica SpA changed compared to last year?

The price-to-earnings ratio of Recordati Industria Chimica e Farmaceutica SpA has increased by 2.98% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Recordati Industria Chimica e Farmaceutica SpA high compared to other companies?

Yes, the price-to-earnings ratio of Recordati Industria Chimica e Farmaceutica SpA is high compared to other companies.

How does an increase in the price-earnings ratio of Recordati Industria Chimica e Farmaceutica SpA affect the company?

An increase in the price-earnings ratio of Recordati Industria Chimica e Farmaceutica SpA would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Recordati Industria Chimica e Farmaceutica SpA affect the company?

A decrease in the price-earnings ratio of Recordati Industria Chimica e Farmaceutica SpA would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Recordati Industria Chimica e Farmaceutica SpA?

Some factors that influence the price-earnings ratio of Recordati Industria Chimica e Farmaceutica SpA are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Recordati Industria Chimica e Farmaceutica SpA pay?

Over the past 12 months, Recordati Industria Chimica e Farmaceutica SpA paid a dividend of 1.17 EUR . This corresponds to a dividend yield of about 2.01 %. For the coming 12 months, Recordati Industria Chimica e Farmaceutica SpA is expected to pay a dividend of 1.25 EUR.

What is the dividend yield of Recordati Industria Chimica e Farmaceutica SpA?

The current dividend yield of Recordati Industria Chimica e Farmaceutica SpA is 2.01 %.

When does Recordati Industria Chimica e Farmaceutica SpA pay dividends?

Recordati Industria Chimica e Farmaceutica SpA pays a quarterly dividend. This is distributed in the months of June, December, June, December.

How secure is the dividend of Recordati Industria Chimica e Farmaceutica SpA?

Recordati Industria Chimica e Farmaceutica SpA paid dividends every year for the past 0 years.

What is the dividend of Recordati Industria Chimica e Farmaceutica SpA?

For the upcoming 12 months, dividends amounting to 1.25 EUR are expected. This corresponds to a dividend yield of 2.15 %.

In which sector is Recordati Industria Chimica e Farmaceutica SpA located?

Recordati Industria Chimica e Farmaceutica SpA is assigned to the 'Health' sector.

Wann musste ich die Aktien von Recordati Industria Chimica e Farmaceutica SpA kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Recordati Industria Chimica e Farmaceutica SpA from 11/20/2024 amounting to 0.6 EUR, you needed to have the stock in your portfolio before the ex-date on 11/18/2024.

When did Recordati Industria Chimica e Farmaceutica SpA pay the last dividend?

The last dividend was paid out on 11/20/2024.

What was the dividend of Recordati Industria Chimica e Farmaceutica SpA in the year 2024?

In the year 2024, Recordati Industria Chimica e Farmaceutica SpA distributed 1.17 EUR as dividends.

In which currency does Recordati Industria Chimica e Farmaceutica SpA pay out the dividend?

The dividends of Recordati Industria Chimica e Farmaceutica SpA are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Recordati Industria Chimica e Farmaceutica SpA

Our stock analysis for Recordati Industria Chimica e Farmaceutica SpA Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Recordati Industria Chimica e Farmaceutica SpA Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.